Ads
related to: Cologuard Dna Test and Colorectal Cancer- How To Order
Cologuard Makes Ordering Simple
With A Range Of Ordering Options.
- Cologuard® FAQs
Find Anwers To The Most
Commonly Asked Questions.
- Contact Us
Find A Representative For Dedicated
HCP Support And General Questions.
- Cologuard® Patient Site
Request A Cologuard® Prescription
From Your Provider Or Online Today.
- Eligible Patients
For Patients 45 And Older
At Average Risk For Colon Cancer.
- Coverage And Support
Find Cologuard® Coverage And
Support For Your Patients.
- How To Order
Search results
Guardant Health's colorectal cancer screening blood test gets thumbs-up from FDA panel
FierceBiotech· 2 weeks agoGuardant Health’s blood test designed to help screen the population for hidden cases of colorectal ...
FDA panel backs Guardant’s blood test for colon cancer
MedTech Dive via Yahoo Finance· 2 weeks agoGuardant rival Exact Sciences is also developing a blood test for colorectal cancer and makes the ...
AgelessRx Expands Preventative Care Offerings with Launch of Cologuard Consultations for Early...
Digital Journal· 1 week agoColorectal cancer is one of the most common cancers diagnosed in both men and women, yet it is highly preventable and treatable when detected early. < ...
Peninsula cancer test maker lands key nod from FDA panel, a step toward a big payday - San Francisco...
The Business Journals· 2 weeks agoShares of Guardant Health Inc. closed Friday more than 13% higher day-over-day, after the Palo Alto...
Is Exact Sciences (EXAS) Too Good to Be True? A Comprehensive An
Guru Focus· 2 weeks agoValue-focused investors are constantly searching for stocks trading below their intrinsic value. Exact Sciences Corp (EXAS), with its current stock price at $51
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Q2 2024 EPS Estimates for Exact Sciences Co. Lowered by William Blair (NASDAQ:EXAS)
ETF DAILY NEWS· 22 hours agoExact Sciences Co. (NASDAQ:EXAS – Free Report) – Stock analysts at William Blair decreased their Q2 2024 earnings per share estimates for shares of Exact Sciences in a research note issued to ...
Ad
related to: Cologuard Dna Test and Colorectal Cancer